MedTrace Logo

Chronic Hepatitis C and Insulin Resistance

NCT00707603 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2015-07-14

No results posted yet for this study

Summary

Chronic hepatitis C (CHC) is among the commonest chronic infectious disease in Australia with \>200,000 exposed persons. Amongst non-infectious chronic conditions- Type 2 diabetes, obesity and heart disease are extremely common. This study will examine the relationship between insulin resistance, fat deposition in the liver, muscle and abdomen, and liver injury due to CHC

Conditions

Sponsors & Collaborators

  • Garvan Institute of Medical Research

    lead OTHER

Principal Investigators

  • Donald Chisholm, MBBS, FRACP · Garvan Institute of Medical Research

  • Jacob George, MBBS, FRACP · Storr Liver Unit

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00707603 on ClinicalTrials.gov